<DOC>
	<DOCNO>NCT00945932</DOCNO>
	<brief_summary>This study measure effect repeat inhale dos GW870086X lung function .</brief_summary>
	<brief_title>A Study Evaluate Effect Repeat Doses GW870086X Mild Moderate Asthmatics</brief_title>
	<detailed_description />
	<criteria>Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhoea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml oestradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 9095 hour postlast dose . Body weight , men &gt; /= 50 kg , woman &gt; /= 45 kg BMI within range 19.0 29.0 kg/m2 ( inclusive ) . Documented history bronchial asthma , first diagnose least 6 month prior screen visit currently treat intermittent shortacting beta2 agonist therapy inhalation . Severity Disease : A best FEV1 40 % 85 % predict normal value Visit 1 screen period . No history smoking within 6 month start study , total pack year history &lt; /= 10 pack year Capable give write informed consent , include compliance requirement restriction list consent form . Single QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin &lt; /= 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . Subject mentally legally incapacitate . Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease ( include confine chronic bronchitis , emphysema , bronchiectasis pulmonary fibrosis ) . Clinically significant abnormality safety laboratory analysis screening . Subject known history hypertension hypertensive screening . Hypertension screen define persistent systolic BP &gt; 140mmHg diastolic BP &gt; 90mmHg . Respiratory tract infection and/or exacerbation asthma within 4 week prior first dose study medication . History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnoea , respiratory arrest and/or hypoxic seizure . Administration oral , injectable dermal steroid within 8 week screen . Administration intranasal and/or inhaled steroid within 2 week screen visit . Prior subject 's maximum daily dose must less FP equivalent 250mcg . Respiratory Infection : Culturedocumented suspect bacterial viral infection upper low respiratory tract , sinus middle ear resolve within 4 week screen lead change asthma management , opinion Investigator expect affect subject asthma status subject ability participate study . Asthma Exacerbation : Any asthma exacerbation require oral corticosteroid within 8 week screen . A subject must hospitalisation asthma within 6 month prior screen The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Paracetamol exception permit daily dos 4 g screen followup . Has take Xanthines ( include theophylline , include caffeine ) , anticholinergic , cromoglycates and/or longacting beta2 agonist within 1 week prior screen unable abstain throughout study . Unable abstain medication include nonsteroidal antiinflammatory drug ( NSAIDs ) , antidepressant drug , antihistamine antiasthma ( include steroid ) , antirhinitis hay fever medication , short act inhaled beta2 agonist paracetamol ( 4 g per day ) treatment minor ailment eg headache 7 day screen followup visit . Unable abstain medication supplement significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 , include ritonavir ketoconazole screen throughout study . Unable use DISKHALER device correctly . History sensitivity study medication ( include lactose ) , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 ml within 56 day period . Unwillingness inability follow procedure outline protocol . Subjects kept due regulatory juridical order institution . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>GW870086X</keyword>
	<keyword>Efficacy</keyword>
	<keyword>FEV1</keyword>
	<keyword>repeat-dose</keyword>
</DOC>